Stan Abel

Stan Abel is President and CEO of ProJenX. He has more than 20 years of senior management and financial experience in the life sciences industry. Under his leadership, executive teams with emerging businesses have identified and in-licensed development-stage drug candidates, raised more than $100 million to fund operations, conducted large-scale clinical trials and implemented successful M&A strategies. Prior to joining ProJenX, Abel held CEO positions at SiteOne Therapeutics Inc. and Corthera Inc. (through its sale to Novartis) with a focus on a new treatment for heart failure. Earlier in his career, Abel was the CFO of Cerexa Inc. and of Peninsula Pharmaceuticals Inc. Abel earned a bachelor’s degree in business from Indiana University and an MBA with honors from the University of Chicago Booth School of Business. He is Chairman of SiteOne Therapeutics and serves as an advisor to early-stage life science companies.